Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets
Where Rebates Eat Into Prices, Volume Makes Up The Difference
Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise.
You may also be interested in...
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
In this week's podcast version of Five Must-Know Things, hear about a research setback in Huntington’s, big R&D investment at Boehringer, a Pfizer divestment in China, Lilly’s biomedicines plans, and the pandemic’s impact on launches and promotion.